Some diabetes drugs may increase risk of bladder cancer

July 3, 2012

An increased risk of bladder cancer is linked to the use of pioglitazone, a medication commonly used to treat type 2 diabetes, according to a new study published in CMAJ (Canadian Medical Association Journal).

People with are at risk of several , including a 40% increased risk of bladder cancer, compared to people without diabetes. Previous studies have shown a higher incidence of bladder cancer in people taking pioglitazone, a type of thiazolidinedione.

To determine whether there is a link between pioglitazone use and bladder cancer, researchers conducted a systematic review and meta-analysis of and observational studies involving over 2.6 million patients.

"We observed an increased risk of bladder cancer associated with the use of thiazolidinediones," writes Dr. Jeffrey Johnson, School of Public Health, University of Alberta, with coauthors. "In particular, use of pioglitazone was associated with an increased risk of bladder cancer based on a pooled estimate from three cohort studies involving more than 1.7 million individuals."

The researchers also looked at a possible association with rosiglitazone, another type of thiazolidinedione, but did not see an effect.

"Although the absolute risk of bladder cancer associated with pioglitazone was small, other evidence-based treatments for type 2 diabetes may be equally effective and do not carry a risk of cancer," conclude the authors. "This study quantifies the association between pioglitazone use and and may help inform decisions around safer use of pioglitazone in individuals with type 2 diabetes."

Explore further: Thiazolidinediones tied to lower cancer risk in diabetes patients

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.112102

Related Stories

Thiazolidinediones tied to lower cancer risk in diabetes patients

April 27, 2012
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.

Diabetes drug linked to increased risk of bladder cancer

May 31, 2012
a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on BMJ today.

Medical societies respond to the FDA's safety announcement on the use of Actos

June 16, 2011
Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated ...

Thiazolidinedione use in patients with Type 2 diabetes may increase risk for diabetic macular edema

June 11, 2012
Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.